Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Rises By 25.5%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 153,000 shares, a growth of 25.5% from the October 15th total of 121,900 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average trading volume of 258,900 shares, the short-interest ratio is presently 0.6 days.

Coeptis Therapeutics Stock Down 3.2 %

NASDAQ COEP traded down $0.01 on Friday, hitting $0.20. 59,360 shares of the company were exchanged, compared to its average volume of 282,862. The company has a current ratio of 0.40, a quick ratio of 0.55 and a debt-to-equity ratio of 0.03. The company has a market cap of $8.18 million, a PE ratio of -0.69 and a beta of -0.94. The stock has a fifty day moving average of $0.19 and a 200-day moving average of $0.24. Coeptis Therapeutics has a 12 month low of $0.15 and a 12 month high of $1.33.

Coeptis Therapeutics (NASDAQ:COEP) last released its quarterly earnings data on Friday, August 16th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. As a group, analysts forecast that Coeptis Therapeutics will post -0.26 earnings per share for the current year.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.